Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440894 | 0.78 | SMN1; SMN2 (0.44) | MBOAT4ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL2431316 | 0.76 | PTGS1 (0.43) | MBOAT4ALDH1A1GRM5MAPK1NPC1 | |
| SCHEMBL2437595 | 0.75 | NOTUM (0.43) | MBOAT4ALDH1A1GRM5MAPK1NPC1 | |
| SCHEMBL12329716 | 0.75 | MBOAT4 (0.46) | MBOAT4ALDH1A1GRM5NPC1RAB9A | |
| SCHEMBL30640206 | 0.75 | NOTUM (0.43) | MBOAT4ALDH1A1GRM5MAPK1NPC1 | |
| SCHEMBL105404 | 0.73 | CYP3A4 (0.47) | CYP3A4ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL30134003 | 0.72 | KDM4E (0.44) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL102595 | 0.72 | KDM4E (0.44) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2799966 | 0.72 | MBOAT4 (0.43) | MBOAT4GRM5MAPTLMNASMN1; SMN2 | |
| SCHEMBL23645571 | 0.71 | MBOAT4 (0.43) | MBOAT4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547679-B1 | 2,3 DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2547679-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | Pfizer Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011114271-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| EP-1399443-B1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. | 2007-06-14 | — | — | US | disclosed |
| US-7141564-B2 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20060213936-A1 | Method of producing and treating twisted beads | CIKO MARCUS J | 2006-09-28 | — | — | US | disclosed |
| EP-1539133-B1 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| US-6991141-B2 | Methods of producing and treating twisted beads | CIKO MARCUS J | 2006-01-31 | — | — | US | disclosed |
| EP-1549156-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | Investigacion Y Nutricion, S.L. (ES) | 2005-07-06 | — | — | EP | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| WO-2004014361-A9 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| EP-1399443-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004014150-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | INVESTIGACION Y NUTRICION, S.L. (ES) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003087098-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | WO | disclosed |
| US-20030136150-A1 | Methods of producing and treating twisted beads | CIKO MARCUS J (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | CYP3A4 1159/4885MBOAT4 4622/4885ALDH1A1 3787/4885 |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | NRDC, NUCB2, NISCH | CYP3A4 1163/4885MBOAT4 4742/4885ALDH1A1 3931/4885 |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | GIPR, GLP1R, GHSR | CYP3A4 4382/4885MBOAT4 395/4885ALDH1A1 1706/4885 |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | QARS1, NQO2, AAAS | CYP3A4 460/4885MBOAT4 4213/4885ALDH1A1 3233/4885 |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | CYP3A4 4410/4885MBOAT4 419/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.